3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Sclerosis, Systemic: new trials by email Literature Review of Sclerosis, Systemic trials Research Report on Sclerosis, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) HZN-825 - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 174 | 2022-11-04 | 2026-01-05 |
| A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis HZN-825 BID, Placebo, HZN-825 QD - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 301 | 2021-11-05 | 2026-03-20 |
| Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease Pomalidomide (CC-4047), Placebo - Scleroderma, Systemic, Sclerosis, Systemic | Phase 2 | Terminated | Celgene | 23 | 2012-08-09 | 2023-12-01 |
Scleroderma, Systemic (3) · Scleroderma, Diffuse (2) · Lung Diseases, Interstitial (1)
Connective Tissue Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Lung Diseases (1) · Respiratory Tract Diseases (1)
pomalidomide (1)
Spain (3) · Italy (2) · Poland (2) · Serbia (2) · United Kingdom (2) · United States (2) · Argentina (1) · Australia (1) · Chile (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Japan (1) · Mexico (1)
2023 (1)